Legal & General Group
XENE icon

Legal & General Group’s Xenon Pharmaceuticals XENE Stock Holding History

Legal & General Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.45M Buy
73,728
+239
+0.3% +$13.3K ﹤0.01% 1650
2026
Q1 		$4.27M Buy
73,489
+3,224
+5% +$149K ﹤0.01% 1580
2025
Q4 		$3.15M Sell
70,265
-9,583
-12% -$402K ﹤0.01% 1798
2025
Q3 		$3.21M Sell
79,848
-1,944
-2% -$68.5K ﹤0.01% 1780
2025
Q2 		$2.56M Buy
81,792
+21,386
+35% +$698K ﹤0.01% 1865
2025
Q1 		$2.03M Hold
60,406
– – ﹤0.01% 1918
2024
Q4 		$2.37M Buy
60,406
+5,286
+10% +$219K ﹤0.01% 1908
2024
Q3 		$2.17M Hold
55,120
– – ﹤0.01% 1928
2024
Q2 		$2.15M Buy
55,120
+110
+0.2% +$4.4K ﹤0.01% 1920
2024
Q1 		$2.37M Buy
55,010
+1,361
+3% +$62.6K ﹤0.01% 1869
2023
Q4 		$2.47M Buy
53,649
+8,936
+20% +$316K ﹤0.01% 1847
2023
Q3 		$1.53M Buy
44,713
+1,921
+4% +$71.9K ﹤0.01% 2016
2023
Q2 		$1.65M Sell
42,792
-4,683
-10% -$186K ﹤0.01% 2004
2023
Q1 		$1.7M Buy
47,475
+31,947
+206% +$1.18M ﹤0.01% 1948
2022
Q4 		$612K Buy
15,528
+3,950
+34% +$144K ﹤0.01% 2288
2022
Q3 		$418K Buy
11,578
+305
+3% +$11K ﹤0.01% 2390
2022
Q2 		$343K Buy
11,273
+502
+5% +$15.2K ﹤0.01% 2448
2022
Q1 		$330K Buy
10,771
+258
+2% +$7.72K ﹤0.01% 2506
2021
Q4 		$328K Buy
10,513
+3,765
+56% +$113K ﹤0.01% 2542
2021
Q3 		$103K Buy
6,748
+5,552
+464% +$96.5K ﹤0.01% 2838
2021
Q2 		$22K Hold
1,196
– – ﹤0.01% 3268
2021
Q1 		$21K Hold
1,196
– – ﹤0.01% 3120
2020
Q4 		$18K Hold
1,196
– – ﹤0.01% 3144
2020
Q3 		$13K Hold
1,196
– – ﹤0.01% 3137
2020
Q2 		$15K Buy
+1,196
New +$15.2K ﹤0.01% 3194

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Legal & General Group's XENE Position: Q2 2026 in Review

Legal & General Group increased its Xenon Pharmaceuticals (XENE) stake by 0.33% in Q2 2026, buying an estimated $13.3K and bringing the position to 73,728 shares worth $4.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1650.

Legal & General Group first reported a position in XENE in Q2 2020 and has held it in 25 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Legal & General Group held 73,728 shares of Xenon Pharmaceuticals worth $4.45M as of Q2 2026.
  • Legal & General Group bought 239 Xenon Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1650 holding.
  • Legal & General Group first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.